Natus Medical Responds to Patent Infringement Allegations Amidst USITC Investigation
Natus Medical's Strategic Response to Patent Allegations
In an important legal maneuver, Natus Medical Incorporated has submitted its official response to the U.S. International Trade Commission (USITC) regarding allegations of patent infringement made by Ceribell, Inc. This action signifies Natus's commitment to not only defending its innovative products but also ensuring continued competition in the medical technology sector.
Background of the Dispute
The current legal challenge stems from a complaint filed by Ceribell, which alleges that Natus has infringed on certain patents associated with wearable electroencephalogram (EEG) devices, particularly those that relate to their recently launched product, BrainWatch. This investigation is centered around claims concerning the violation of section 337 of the Tariff Act of 1930, with Ceribell seeking to impede the sales of BrainWatch in the United States by claiming that it incorporates their patented technologies without permission.
Natus’s response follows a formal request by Ceribell made to the USITC on July 7, 2025, requesting an investigation into the matter. Natus, with its 85-year legacy in healthcare, stands firm in the belief that the allegations have no merit.
Natus's Position
Natus's legal team has articulated several key points in its response:
1. Denial of Infringement: Natus categorically denies all allegations of patent infringement, including claims of
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.